Dyne Therapeutics Gets New FDA Orphan Drug Designation
By Sabela Ojea
Dyne Therapeutics said the U.S. Food and Drug Administration granted orphan drug designation to its DYNE-101 treatment, which targets the multisystem disorder Myotonic Dystrophy Type 1.
The biotechnology company on Wednesday said that DYNE-101 is being evaluated in the Phase 1/2 global achieve clinical trial with initial data on safety expected for the second half of the year.
The orphan drug designation is granted to drugs or biologics intended for treatment, prevention or diagnosis of a rare disease that affects less than 200,000 people in the U.S.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
September 20, 2023 16:36 ET (20:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact